CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study

7039 Background: First line treatment for stage IIIb/IV NSCLC continues to be a combination of a taxane + platinum with partial responses expected in only 20 - 30% of patients. Multiple pre-clinica...